Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial

Journal article

Peer reviewed

B.J. Rimel, A.A. Secord, M.A. Geller, D.S. Miller, N. Cloven, G.F. Fleming, A.E. Wahner Hendrickson, M. Azodi, P. DiSilvestro, A.M. Oza, …

Gynecologic oncology, Vol.156(3), pp.e4-e5

03/2020

Metrics

2 Record Views

Title: Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial
Creators: B.J. Rimel - Cedars-Sinai Medical Center
A.A. Secord - Duke University Health System
M.A. Geller - University of Minnesota Medical Center
D.S. Miller - Southwestern Medical Center
N. Cloven - Texas Oncology
G.F. Fleming - University of Chicago
A.E. Wahner Hendrickson - Mayo Clinic in Arizona
M. Azodi - Yale University
P. DiSilvestro - Women & Infants Hospital of Rhode Island
A.M. Oza - University Health Network
M. Cristea - City Of Hope National Medical Center
J.S. Berek - Cancer Prevention Institute of California
J.K. Chan - Sutter Health
D.E. Matei - Northwestern University
Y. Li - Tesaro
K. Sun - Tesaro
K. Luptakova - Tesaro
U.A. Matulonis - Harvard University
B.J. Monk - University of Arizona
K.N. Moore - University of Oklahoma Health Sciences Center
Publication Details: Gynecologic oncology, Vol.156(3), pp.e4-e5
Publisher: Elsevier Inc
Identifiers: 991005968875802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article